Compare NRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | RNXT |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 79.4M |
| IPO Year | 1995 | 2021 |
| Metric | NRT | RNXT |
|---|---|---|
| Price | $8.46 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 27.1K | ★ 759.1K |
| Earning Date | 09-08-2026 | 11-12-2026 |
| Dividend Yield | ★ 9.57% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 0.70 | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | $12.00 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $5.23 | $0.70 |
| 52 Week High | $10.49 | $2.59 |
| Indicator | NRT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 42.90 |
| Support Level | $8.48 | $0.83 |
| Resistance Level | $8.68 | $1.51 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 42.57 | 12.17 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.